Baricitinib improved morphoea manifestations in a patient with alopecia areata universalis.

In our clinical case, the patient, affected by morphea, reported an excellent response to the administration of baricitinib 4 mg day-1, with rapid disappearance of itching and reduction of the erythematous-infiltrative component of the plaques, highlighting the important role of the JAK/STAT pathway in TGF-β-mediated profibrotic signalling.